ONCORAL PHARMA ApS: Financial statements 2023
CVR: 35481214
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
ONCORAL PHARMA ApS (CVR 35481214) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -996,227 and a net result of DKK -2,667,242 compared with DKK -9,206,889 the year before. Equity in the 2023 report amounted to DKK -29,132,287. The company had 1 employee in the financial year.
- Gross Profit
- DKK -996,227
- Profit/Loss
- DKK -2,667,242
- Equity
- DKK -29,132,287
- Total Assets
- DKK 9,483,045
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -996 t. | -2.7 mio. | -29.1 mio. | 1 |
| 2022 | - | -7.5 mio. | -9.2 mio. | -26.5 mio. | - |
| 2021 | - | -13.8 mio. | -11.8 mio. | -17.3 mio. | - |
| 2020 | - | -3.9 mio. | -3.5 mio. | -5.4 mio. | - |
| 2019 | - | -1.6 mio. | -1.5 mio. | -1.4 mio. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
ONCORAL PHARMA ApS has published its annual report for 2022. Gross profit came to DKK -7,461,588, and the net result was DKK -9,206,889.
About ONCORAL PHARMA ApS
ONCORAL PHARMA ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2013. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Magnus Olafsson Corfitzen. The company is owned by Ascelia Pharma AB. The company has 0 employees (2014). In 2025, the company reported a gross profit of DKK -1,617,542 and a net result of DKK -2,313,169 compared with DKK -4,057,834 the year before. Equity in the 2025 report amounted to DKK -35,503,290.